Susan Knudson
Chief Executive Officer at HISTOGEN INC.
Net worth: - $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dan Kisner | M | 77 | 10 years | |
| David Crean | M | 59 | 4 years | |
| Elizabeth Hougen | F | 62 | 24 years | |
| Rochelle Fuhrmann | F | 54 | 3 years | |
| Jonathan Jackson | M | 62 | 4 years | |
| Brian Satz | M | 51 | 4 years | |
| Susan Windham-Bannister | M | 74 | 3 years | |
| Mark A. Hubka | M | - | - | |
| Thomas L. Hubka | M | 37 | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Mento | M | 72 | 18 years | |
| George W. Mahaffey | M | 65 |
Neothetics, Inc.
 Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 5 years |
| Richard Pascoe | M | 60 | 1 years | |
| Gail Naughton | M | 69 | 16 years | |
| John Dobak | M | 58 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 7 years |
| Maria Feldman | F | - |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
| Eun-Young Cha | M | 61 |
University of San Diego
| 3 years |
| Magda Marquet | M | 65 | 1 years | |
| Sigurdur Olafsson | M | 55 | 2 years | |
| Stephen M. Chang | M | 68 | 1 years | |
| Kim Kamdar | M | 56 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
| Brian Frederick Caine | M | 66 |
University of San Diego
| 7 years |
| Maria C. Roberts | F | - |
University of San Diego
| 7 years |
| Moya M. Daniels | F | 55 | 1 years | |
| Maxim Gorbachev | M | 48 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
| Dennis Fenton | M | 72 | 4 years | |
| Jeffrey M. Nugent | M | 76 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
| Yizhuo Zhang | M | 35 | 1 years | |
| Lorianne K. Masuoka | M | 62 | 1 years | |
| Bret E. Megargel | M | 55 |
Avera Pharmaceuticals, Inc.
 Avera Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA. | 2 years |
| Martha Demski | F | 71 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 4 years |
| Daniel Janney | M | 58 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 8 years |
| Michael Rish | M | - |
University of San Diego
| 4 years |
| Henry James Darcey | M | - |
University of San Diego
| 5 years |
| Van A. Tengberg | M | - |
University of San Diego
| 3 years |
| W. Gerard von Hoffmann | M | - |
University of San Diego
| 3 years |
| Nicodemus M. Trisnadi | M | 60 |
University of San Diego
| 4 years |
| Gary R. Dokes | M | - |
University of San Diego
| 2 years |
| Encik Saffie bin Bakar | M | 71 |
University of San Diego
| 2 years |
| Valerie V. Vekkos | F | - |
University of San Diego
| 3 years |
| Jeff S. Rowerdink | M | - |
University of San Diego
| 4 years |
| Douglas K. Freeman | M | - |
University of San Diego
| 3 years |
| Erik Swain | M | - |
University of San Diego
| 4 years |
| David N. Shafer | M | 71 |
University of San Diego
| 1 years |
| Steve O'Brien | M | - |
University of San Diego
| 3 years |
| Daniel White | M | 62 |
University of San Diego
| 4 years |
| Lawrence Goldman | M | - |
University of San Diego
| 4 years |
| Brian A. Lebrecht | M | - |
University of San Diego
| 4 years |
| Daniel Keith Speirsm | M | - |
University of San Diego
| 4 years |
| Julie M. Maloy | F | - |
University of San Diego
| 4 years |
| Ido Levanon | M | - |
University of San Diego
| 2 years |
| John Schmieder | M | 55 |
University of San Diego
| 4 years |
| Chris Andaya | M | - |
University of San Diego
| 4 years |
| Theresa A. Cherry | F | - |
University of San Diego
| 4 years |
| Conn R. Flanigan | M | 55 |
University of San Diego
| 4 years |
| Tony Lombardo | M | - |
University of San Diego
| 4 years |
| Tyler van Buren | M | - |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 2 years |
| Scott Huckleberry | M | - |
University of San Diego
| 4 years |
| Michael DeMayo | M | 65 |
University of San Diego
| 3 years |
| Nadine Knowles | F | - |
Avera Pharmaceuticals, Inc.
Avera Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA. | - |
| Jeff Solomon | M | - |
University of San Diego
| 3 years |
| Avis Thomas | F | 60 |
University of San Diego
| 4 years |
| Jim A. Spina | M | - |
University of San Diego
| 5 years |
| Jody J. Fouch | M | - |
University of San Diego
| 4 years |
| Alison Jones Gamble | F | - |
University of San Diego
| 4 years |
| Steven Osgood | M | 67 |
University of San Diego
| 2 years |
| Donald C. Mueller | M | 60 |
University of San Diego
| 4 years |
| Faye H. Russell | F | - |
University of San Diego
| 3 years |
| Lori A. Johnstone | F | - |
University of San Diego
| 2 years |
| Lisa R. Grillone | M | 74 | 10 years | |
| Hani M. Zeini | M | 59 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
| Uzi Zimmerman | M | - |
University of San Diego
| 4 years |
| John L. Morrell | M | - |
University of San Diego
| 3 years |
| Eileen Hoffmann | F | - |
University of San Diego
| 4 years |
| Thomas Wiggans | M | 72 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 3 years |
| William R. Shanahan | M | 74 | 6 years | |
| Ana Wiechers Marshall | F | - |
University of San Diego
| 4 years |
| Byron Roth | M | 61 |
University of San Diego
| 4 years |
| Patricia Walker | M | 64 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 1 years |
| Lincoln Krochmal | M | 78 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 3 years |
| Craig Earle Courter | M | - |
University of San Diego
| 3 years |
| Jella Susanne Benner-Heinacher | F | 64 |
University of San Diego
| 3 years |
| Thomas D. Franklin | M | - |
University of San Diego
| 4 years |
| Frank Reilly | M | - |
University of San Diego
| 1 years |
| John Penrith | M | 55 |
University of San Diego
| 4 years |
| David R. Czajkowski | M | - |
University of San Diego
| 4 years |
| Kim Wahl | M | 64 |
University of San Diego
| 4 years |
| Li-An C. Leonard | F | - |
University of San Diego
| 4 years |
| Alfred Spada | M | 66 | - | |
| Dinu Sen | M | - |
Avera Pharmaceuticals, Inc.
Avera Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA. | - |
| Michael Fritz Herbert Bonte Friedheim | M | 58 |
University of San Diego
| 5 years |
| Robert P. Troy | M | - |
University of San Diego
| 3 years |
| Jack R. Mitchell | M | 68 |
University of San Diego
| 3 years |
| Joao Siffert | M | 60 |
Avera Pharmaceuticals, Inc.
Avera Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA. | 2 years |
| Valorie Seyfert | F | - |
University of San Diego
| 3 years |
| Jeanne M. Bonk | F | - |
University of San Diego
| 4 years |
| Lawrence W. Shea | M | - |
University of San Diego
| 3 years |
| Vito A. Canuso | M | 64 |
University of San Diego
| 3 years |
| Terry Schmidt | F | 62 |
University of San Diego
| 4 years |
| Brian J. Quinn | M | - |
University of San Diego
| 4 years |
| Philip Palumbo | M | - |
University of San Diego
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Susan Knudson
- Personal Network
